Contact
searchSearch
HMP Global
Login
Andrea Apolo, MD, National Cancer Institute
Conference Coverage
Adjuvant Pembrolizumab New Therapeutic Option For High-Risk Muscle-Invasive Bladder Cancer
02/05/2024
At the 2024 ASCO GU Cancers Symposium, Andrea Apolo, MD, shared insights from the phase 3 AMBASSADOR Alliance AO31501 study, looking at adjuvant pembrolizumab for patients with muscle-invasive bladder cancer at a high risk for recurrence.
At the 2024 ASCO GU Cancers Symposium, Andrea Apolo, MD, shared insights from the phase 3 AMBASSADOR Alliance AO31501 study, looking at adjuvant pembrolizumab for patients with muscle-invasive bladder cancer at a high risk for recurrence.
At the 2024 ASCO GU Cancers...
02/05/2024
Oncology
Benjamin Lowentritt, MD
Conference Coverage
Real-World Response to Apalutamide vs Enzalutamide for Metastatic Castration-Resistant Prostate Cancer
01/31/2024
Benjamin Lowentritt share results from a study of real-world data which found more patients with metastatic castration-resistant prostate cancer had a deep, early PSA response to apalutamide than enzalutamide.
Benjamin Lowentritt share results from a study of real-world data which found more patients with metastatic castration-resistant prostate cancer had a deep, early PSA response to apalutamide than enzalutamide.
Benjamin Lowentritt share...
01/31/2024
Oncology
Enrique Grande, MD, PhD
Conference Coverage
Cabozantinib Plus Atezolizumab Showed Modest Activity Among Patients With Advanced Adrenocortical Carcinoma
01/31/2024
Enrique Grande, MD, shared results from the phase 2 CABATEN study, which evaluated the activity and safety of cabozantinib plus atezolizumab among patients with locally advanced or metastatic adrenocortical carcinoma.
Enrique Grande, MD, shared results from the phase 2 CABATEN study, which evaluated the activity and safety of cabozantinib plus atezolizumab among patients with locally advanced or metastatic adrenocortical carcinoma.
Enrique Grande, MD, shared...
01/31/2024
Oncology
Conference Coverage
Nivolumab Plus Ipilimumab Improved Survival, Response Compared to Sunitinib Among Patients With Advanced Clear Cell Renal Cell Carcinoma
01/31/2024
Long-term follow-up data from the phase 3 CheckMate-214 trial demonstrated that nivolumab plus ipilimumab improved survival and response compared to sunitinib among patients with advanced renal cell carcinoma.
Long-term follow-up data from the phase 3 CheckMate-214 trial demonstrated that nivolumab plus ipilimumab improved survival and response compared to sunitinib among patients with advanced renal cell carcinoma.
Long-term follow-up data from...
01/31/2024
Oncology
David Aggen, MD, PhD
Conference Coverage
HER2 and PD-L1 Immunohistochemistry Expression Among Patients With Advanced Bladder Cancer
01/30/2024
David Aggen, MD, shares insights from a retrospective analysis done to evaluate the association between HER2 mutation/amplification, HER2, and PD-L1 immunohistochemistry expression, and associations with clinical outcomes for advanced bladder...
David Aggen, MD, shares insights from a retrospective analysis done to evaluate the association between HER2 mutation/amplification, HER2, and PD-L1 immunohistochemistry expression, and associations with clinical outcomes for advanced bladder...
David Aggen, MD, shares insights...
01/30/2024
Oncology
Thomas Powles, MBBS, MD
Conference Coverage
Belzutifan Improves Quality of Life Among Patients With Advanced Clear Cell Renal Cell Carcinoma
01/27/2024
Thomas Powles, MBBS, MD, discusses results from the phase 3 LITESPARK-005 study which compared patient-reported outcomes among patients treated with belzutifan and everolimus for advanced/metastatic clear cell renal cell carcinoma.
Thomas Powles, MBBS, MD, discusses results from the phase 3 LITESPARK-005 study which compared patient-reported outcomes among patients treated with belzutifan and everolimus for advanced/metastatic clear cell renal cell carcinoma.
Thomas Powles, MBBS, MD,...
01/27/2024
Oncology
Conference Coverage
Adjuvant Pembrolizumab Succeeds For Patients With Renal Cell Carcinoma At Increased Risk of Relapse
01/27/2024
Adjuvant pembrolizumab significantly improved overall survival among patients with renal cell carcinoma at an increased risk for recurrence after surgery, when compared with placebo.
Adjuvant pembrolizumab significantly improved overall survival among patients with renal cell carcinoma at an increased risk for recurrence after surgery, when compared with placebo.
Adjuvant pembrolizumab...
01/27/2024
Oncology
Conference Coverage
Adjuvant Nivolumab Failed to Meet End Point for Patients With Renal Cell Carcinoma
01/27/2024
In Part B of CheckMate 914, adjuvant nivolumab monotherapy failed to meet the primary end point of disease-free survival for patients with renal cell carcinoma at high risk of relapse following nephrectomy.
In Part B of CheckMate 914, adjuvant nivolumab monotherapy failed to meet the primary end point of disease-free survival for patients with renal cell carcinoma at high risk of relapse following nephrectomy.
In Part B of CheckMate 914,...
01/27/2024
Oncology
Saby George, MD
Conference Coverage
Subcutaneous Nivolumab Noninferior to Intravenous Administration Among Patients With Clear Cell Renal Cell Carcinoma
01/27/2024
Saby George shares insights from the CheckMate 67T evaluating the subcutaneous administration of nivolumab for patients with clear cell renal cell carcinoma, compared with the intravenous administration.
Saby George shares insights from the CheckMate 67T evaluating the subcutaneous administration of nivolumab for patients with clear cell renal cell carcinoma, compared with the intravenous administration.
Saby George shares insights from...
01/27/2024
Oncology
Michiel van der Heijden, MD 
Conference Coverage
Enfortumab Vedotin Plus Pembrolizumab Potential New Standard of Care for Advanced Urothelial Carcinoma in the First-Line Setting
01/26/2024
Michiel van der Heijden, MD, discusses the subgroup analyses of the phase 3 EV-302 study, evaluating enfortumab vedotin plus pembrolizumab among patients with locally advanced or metastatic urothelial carcinoma in the first-line setting.
Michiel van der Heijden, MD, discusses the subgroup analyses of the phase 3 EV-302 study, evaluating enfortumab vedotin plus pembrolizumab among patients with locally advanced or metastatic urothelial carcinoma in the first-line setting.
Michiel van der Heijden, MD,...
01/26/2024
Oncology
Conference Coverage
Adjuvant Pembrolizumab Improved Disease-Free Survival Among Patients With Muscle-Invasive Bladder Cancer
01/26/2024
Interim DFS/OS results from the phase 3 AMBASSADOR Alliance AO31501 study demonstrated adjuvant pembrolizumab improved DFS among patients with high-risk muscle-invasive urothelial carcinoma.
Interim DFS/OS results from the phase 3 AMBASSADOR Alliance AO31501 study demonstrated adjuvant pembrolizumab improved DFS among patients with high-risk muscle-invasive urothelial carcinoma.
Interim DFS/OS results from the...
01/26/2024
Oncology
Neal Shore, MD, Carolina Urologic Research Center
Conference Coverage
Impact of Suspended Enzalutamide Monotherapy on Metastasis-Free Survival Among Patients With High-Risk Biochemically Recurrent Prostate Cancer
01/26/2024
Neal Shore, MD, discusses results from the phase 3 EMBARK trial, evaluating treatment suspension among patients with high-risk biochemically recurrent prostate cancer.
Neal Shore, MD, discusses results from the phase 3 EMBARK trial, evaluating treatment suspension among patients with high-risk biochemically recurrent prostate cancer.
Neal Shore, MD, discusses...
01/26/2024
Oncology
Conference Coverage
Oral APL-1202 Plus Tislelizumab Shows Promise in Neoadjuvant Setting Among Patients With Muscle-Invasive Bladder Cancer
01/26/2024
According to results from a phase 1/2 study, the combination of oral APL-1202 and tislelizumab in the neoadjuvant setting showed promising activity and safety among patients with muscle-invasive bladder cancer.
According to results from a phase 1/2 study, the combination of oral APL-1202 and tislelizumab in the neoadjuvant setting showed promising activity and safety among patients with muscle-invasive bladder cancer.
According to results from a...
01/26/2024
Oncology
Conference Coverage
Cognitive Function Similar Between Patients With mCRPC Treated With Abiraterone Acetate or Enzalutamide
01/25/2024
Results from the ACE study suggest that patients with metastatic castration-resistant prostate cancer treated with either abiraterone acetate or enzalutamide have a comparable composite cognitive outcome, though patients treated with...
Results from the ACE study suggest that patients with metastatic castration-resistant prostate cancer treated with either abiraterone acetate or enzalutamide have a comparable composite cognitive outcome, though patients treated with...
Results from the ACE study...
01/25/2024
Oncology
Conference Coverage
Olaparib Plus Abiraterone and Prednisone Improved Progression-Free Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and HRR Mutations
01/25/2024
According to a phase 2 trial, olaparib plus abiraterone/prednisone improved the progression-free survival among patients with metastatic castration-resistant prostate cancer with BRCA1/2 or ATM mutations, compared to either agent alone or...
According to a phase 2 trial, olaparib plus abiraterone/prednisone improved the progression-free survival among patients with metastatic castration-resistant prostate cancer with BRCA1/2 or ATM mutations, compared to either agent alone or...
According to a phase 2 trial,...
01/25/2024
Oncology
Conference Coverage
Cabozantinib Plus Atezolizumab Significantly Prolonged PFS in Metastatic Castration-Resistant Prostate Cancer
01/25/2024
Results from the ongoing phase 3 CONTACT-2 trial demonstrated that cabozantinib plus atezolizumab significantly improved rPFS compared to abiraterone plus prednisone or enzalutamide among patients with metastatic castration-resistant prostate...
Results from the ongoing phase 3 CONTACT-2 trial demonstrated that cabozantinib plus atezolizumab significantly improved rPFS compared to abiraterone plus prednisone or enzalutamide among patients with metastatic castration-resistant prostate...
Results from the ongoing phase 3...
01/25/2024
Oncology
Conference Coverage
Dose-Escalated Radiotherapy Plus Long-Term Androgen-Deprivation Therapy Deemed Safe, Effective for High-Risk Prostate Cancer
01/25/2024
According to a phase 3 trial, dose-escalated radiotherapy combined with long-term androgen deprivation therapy improved the survival outcomes, without increasing toxicities, among patients with high-risk prostate cancer.
According to a phase 3 trial, dose-escalated radiotherapy combined with long-term androgen deprivation therapy improved the survival outcomes, without increasing toxicities, among patients with high-risk prostate cancer.
According to a phase 3 trial,...
01/25/2024
Oncology
News
Nivolumab Plus Chemotherapy Following TURBT for Patients With Muscle-Invasive Bladder Cancer
05/02/2023
According to a phase 2 study, post-TURBT gemcitabine-cisplatin plus nivolumab conveyed a high complete response rate for patients with muscle-invasive bladder cancer, with many responders going on to achieve 2-year bladder-intact...
According to a phase 2 study, post-TURBT gemcitabine-cisplatin plus nivolumab conveyed a high complete response rate for patients with muscle-invasive bladder cancer, with many responders going on to achieve 2-year bladder-intact...
According to a phase 2 study,...
05/02/2023
Oncology
Dan Petrylak, MD, Yale Cancer Center
Videos
No Improvement to Survival Outcomes With Pembrolizumab Plus Docetaxel for Castration-Resistant Prostate Cancer
03/10/2023
Daniel Petrylak, MD, discusses an abstract presented at 2023 ASCO Genitourinary Cancers Symposium, evaluating pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer.
Daniel Petrylak, MD, discusses an abstract presented at 2023 ASCO Genitourinary Cancers Symposium, evaluating pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer.
Daniel Petrylak, MD, discusses...
03/10/2023
Oncology
Neeraj Agarwal, MD, Huntsman Cancer Institute
Videos
Talazoparib Plus Enzalutamide Improves PFS in Metastatic Castration-Resistant Prostate Cancer
03/08/2023
At the 2023 ASCO Genitourinary Cancers Symposium, Neeraj Agarwal, MD, presented results from a phase 3 trial evaluating enzalutamide plus talazoparib vs enzalutamide plus placebo for patients with metastatic castration-resistant prostate...
At the 2023 ASCO Genitourinary Cancers Symposium, Neeraj Agarwal, MD, presented results from a phase 3 trial evaluating enzalutamide plus talazoparib vs enzalutamide plus placebo for patients with metastatic castration-resistant prostate...
At the 2023 ASCO Genitourinary...
03/08/2023
Oncology
Siamak Daneshmand, MD, Norris Comprehensive Cancer Center at USC
Videos
Erdafitinib for Patients With Intermediate-Risk Non-Muscle Invasive Bladder Cancer
03/02/2023
At the 2023 ASCO GU Cancers Symposium, Siamak Daneshmand, MD, reported interim analysis results from Cohort 3 of the phase 2 THOR-2 trial.
At the 2023 ASCO GU Cancers Symposium, Siamak Daneshmand, MD, reported interim analysis results from Cohort 3 of the phase 2 THOR-2 trial.
At the 2023 ASCO GU Cancers...
03/02/2023
Oncology
Nicholas Van As, MMBCh, Royal Marsden Hospital
Videos
Quality of Life Outcomes: SBRT vs Surgery for Patients with Localized Prostate Cancer
03/02/2023
At the 2023 ASCO GU Cancers Symposium, Nicholas Van As, MMBCh, discusses the results from the PACE-A trial, comparing quality of life outcomes from surgery vs SBRT with localized prostate cancer.
At the 2023 ASCO GU Cancers Symposium, Nicholas Van As, MMBCh, discusses the results from the PACE-A trial, comparing quality of life outcomes from surgery vs SBRT with localized prostate cancer.
At the 2023 ASCO GU Cancers...
03/02/2023
Oncology
James Catto, MB, ChB, PhD, University of Sheffield
Videos
Erdafitinib for Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
03/02/2023
At the 2023 ASCO GU Cancers Symposium, James Catto, MB, ChB, PhD, discusses results from Cohort 2 of a phase 2 trial evaluating erdafitinib among patients with bacillus Calmette-Guérin (BCG)-unresponsive, high risk, non-muscle-invasive...
At the 2023 ASCO GU Cancers Symposium, James Catto, MB, ChB, PhD, discusses results from Cohort 2 of a phase 2 trial evaluating erdafitinib among patients with bacillus Calmette-Guérin (BCG)-unresponsive, high risk, non-muscle-invasive...
At the 2023 ASCO GU Cancers...
03/02/2023
Oncology
Daniel Geynisman, MD, Fox Chase Cancer Center
Videos
Risk-Adapted Approach for Muscle-Invasive Bladder Cancer Requires Further Refinement
03/01/2023
At the 2023 ASCO GU Cancers Symposium, Daniel Geynisman, MD, shares results of a trial examining a risk-adapted approach to treatment for patients with muscle-invasive bladder cancer.
At the 2023 ASCO GU Cancers Symposium, Daniel Geynisman, MD, shares results of a trial examining a risk-adapted approach to treatment for patients with muscle-invasive bladder cancer.
At the 2023 ASCO GU Cancers...
03/01/2023
Oncology
Srikala Sridhar, MD, Princess Margaret Cancer Center
Videos
Avelumab Maintenance for Urothelial Carcinoma by First-Line Chemotherapy Regimen
02/28/2023
At the 2023 ASCO GU Cancers Symposium, Srikala Sridhar, MD, shares results and insights from the long-term follow-up of the JAVELIN Bladder 001 trial.
At the 2023 ASCO GU Cancers Symposium, Srikala Sridhar, MD, shares results and insights from the long-term follow-up of the JAVELIN Bladder 001 trial.
At the 2023 ASCO GU Cancers...
02/28/2023
Oncology
Gwenaelle Gravis, MD, Institute Paoli-Calmettes
Videos
Safety of Apalutamide vs Active Surveillance for Prostate Cancer
02/27/2023
At 2023 ASCO Genitourinary Cancers Symposium, Gwenaelle Gravis, MD, presented a study evaluating the addition of apalutamide to active surveillance for patients with low to intermediate risk prostate cancer.
At 2023 ASCO Genitourinary Cancers Symposium, Gwenaelle Gravis, MD, presented a study evaluating the addition of apalutamide to active surveillance for patients with low to intermediate risk prostate cancer.
At 2023 ASCO Genitourinary...
02/27/2023
Oncology
Eleni Efstathiou, MD, Houston Methodist Cancer Center
Videos
Niraparib Plus Abiraterone and Prednisone for Patients With Castration-Resistant Prostate Cancer and HRR Alterations
02/27/2023
At 2023 ASCO Genitourinary Cancers Symposium, Eleni Efstathiou, MD, shared phase 3 data which support the use of niraparib with abiraterone acetate and prednisone among patients with metastatic castration-resistant prostate cancer and BRCA...
At 2023 ASCO Genitourinary Cancers Symposium, Eleni Efstathiou, MD, shared phase 3 data which support the use of niraparib with abiraterone acetate and prednisone among patients with metastatic castration-resistant prostate cancer and BRCA...
At 2023 ASCO Genitourinary...
02/27/2023
Oncology
Conference Coverage
Radiolabeled 89Zr-DFO-girentuximab PET/CT Imaging Accurately Identifies Clear Cell Renal Cell Carcinoma
02/22/2023
According to phase 3 results presented at the 2023 ASCO GU Cancers Symposium, radiolabeled 89Zr-DFO-girentuximab (TLX250-CDx) PET/CT was able to accurately identify clear cell renal cell carcinoma.
According to phase 3 results presented at the 2023 ASCO GU Cancers Symposium, radiolabeled 89Zr-DFO-girentuximab (TLX250-CDx) PET/CT was able to accurately identify clear cell renal cell carcinoma.
According to phase 3 results...
02/22/2023
Oncology
Conference Coverage
Neoadjuvant Chemotherapy Plus Radical Cystectomy Superior to Trimodality Therapy for Early-Stage Small Cell Bladder Cancer
02/22/2023
According to results presented at the 2023 ASCO GU Cancers Symposium, neoadjuvant chemotherapy plus radical cystectomy improved overall survival rates among patients with early-stage small cell bladder cancer compared to trimodality therapy.
According to results presented at the 2023 ASCO GU Cancers Symposium, neoadjuvant chemotherapy plus radical cystectomy improved overall survival rates among patients with early-stage small cell bladder cancer compared to trimodality therapy.
According to results presented...
02/22/2023
Oncology
Conference Coverage
Nivolumab Plus Cabozantinib Benefits Consistent at 3 Years for Renal Cell Carcinoma
02/21/2023
According to 3-year follow-up data presented at the 2023 ASCO GU Symposium, nivolumab plus cabozantinib continues to demonstrate benefits in survival and response for patients with advanced renal cell carcinoma, compared with sunitinib.
According to 3-year follow-up data presented at the 2023 ASCO GU Symposium, nivolumab plus cabozantinib continues to demonstrate benefits in survival and response for patients with advanced renal cell carcinoma, compared with sunitinib.
According to 3-year follow-up...
02/21/2023
Oncology
Conference Coverage
Sacituzumab Govitecan Improved Response Rate Among Platinum-Ineligible Patients With Urothelial Carcinoma
02/21/2023
According to results presented at the 2023 ASCO GU Cancers Symposium, sacituzumab govitecan monotherapy resulted in heightened response rates among platinum-ineligible patients with metastatic urothelial carcinoma who progressed following...
According to results presented at the 2023 ASCO GU Cancers Symposium, sacituzumab govitecan monotherapy resulted in heightened response rates among platinum-ineligible patients with metastatic urothelial carcinoma who progressed following...
According to results presented...
02/21/2023
Oncology
Andrew Katims, MD, Memorial Sloan Kettering Cancer Center
Videos
Assessing the MSK-ACCESS ctDNA Assay in Node-Positive Muscle-Invasive Bladder Cancer
02/21/2023
At the 2023 ASCO GU Cancers Symposium, Andrew Katims, MD, presents results from an assessment of a ctDNA assay in node-positive muscle-invasive bladder cancer.
At the 2023 ASCO GU Cancers Symposium, Andrew Katims, MD, presents results from an assessment of a ctDNA assay in node-positive muscle-invasive bladder cancer.
At the 2023 ASCO GU Cancers...
02/21/2023
Oncology
Kyle Rose, MD, Moffitt Cancer Center & Research Institute
Videos
Urinary Tumor DNA for Minimal Residual Disease Detection at Repeat TURBT in Non-Muscle-Invasive Bladder Cancer
02/21/2023
At the 2023 ASCO GU Cancers Symposium, Kyle Rose, MD, presents results from a prospective study investigating urinary tumor DNA as a surrogate for minimal residual disease among patients with NMIBC undergoing repeat TURBT.
At the 2023 ASCO GU Cancers Symposium, Kyle Rose, MD, presents results from a prospective study investigating urinary tumor DNA as a surrogate for minimal residual disease among patients with NMIBC undergoing repeat TURBT.
At the 2023 ASCO GU Cancers...
02/21/2023
Oncology
Conference Coverage
Abiraterone Plus Olaparib Prolonged rPFS, Improved OS Among Patients With Castration-Resistant Prostate Cancer
02/17/2023
According to results presented at the 2023 ASCO GU Cancers Symposium, the randomized, double-blind, phase 3 PROpel study found abiraterone acetate plus olaparib prolonged radiographic progression-free survival and improved overall survival...
According to results presented at the 2023 ASCO GU Cancers Symposium, the randomized, double-blind, phase 3 PROpel study found abiraterone acetate plus olaparib prolonged radiographic progression-free survival and improved overall survival...
According to results presented...
02/17/2023
Oncology
Conference Coverage
Tislelizumab Plus Radiotherapy for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer
02/17/2023
According to preliminary results from a phase 2 trial presented at the 2023 ASCO GU Symposium, tislelizumab plus radiotherapy shows promise as a bladder-preserving therapy for BCG-unresponsive patients with non-muscle-invasive bladder cancer...
According to preliminary results from a phase 2 trial presented at the 2023 ASCO GU Symposium, tislelizumab plus radiotherapy shows promise as a bladder-preserving therapy for BCG-unresponsive patients with non-muscle-invasive bladder cancer...
According to preliminary results...
02/17/2023
Oncology
Conference Coverage
Nivolumab Benefit Continues At 3 Years for Muscle-Invasive Urothelial Carcinoma Post-Resection
02/17/2023
According to follow-up data presented at the 2023 ASCO GU Cancers Symposium, nivolumab continued to show benefit in survival outcomes among patients with high-risk muscle-invasive urothelial carcinoma after radical resection.
According to follow-up data presented at the 2023 ASCO GU Cancers Symposium, nivolumab continued to show benefit in survival outcomes among patients with high-risk muscle-invasive urothelial carcinoma after radical resection.
According to follow-up data...
02/17/2023
Oncology
Aristotelis Bamias, MD, University of Athens
Videos
Atezolizumab Monotherapy vs Chemotherapy for Patients with Metastatic Urothelial Carcinoma
02/17/2023
At the 2023 ASCO Genitourinary Cancer Symposium, Aristotelis Bamias, MD, discusses overall survival results from the IMvigor130 study, evaluating atezolizumab monotherapy and platinum/gemcitabine chemotherapy among previously untreated...
At the 2023 ASCO Genitourinary Cancer Symposium, Aristotelis Bamias, MD, discusses overall survival results from the IMvigor130 study, evaluating atezolizumab monotherapy and platinum/gemcitabine chemotherapy among previously untreated...
At the 2023 ASCO Genitourinary...
02/17/2023
Oncology
Conference Coverage
Pembrolizumab Monotherapy Shows Activity Among BCG-Unresponsive Patients With Non-CIS, Papillary NMIBC
02/17/2023
According to study results presented at the 2023 ASCO GU Cancers Symposium, pembrolizumab monotherapy showed antitumor activity for patients with non-carcinoma in situ, papillary, high-risk non-muscle-invasive bladder cancer who were...
According to study results presented at the 2023 ASCO GU Cancers Symposium, pembrolizumab monotherapy showed antitumor activity for patients with non-carcinoma in situ, papillary, high-risk non-muscle-invasive bladder cancer who were...
According to study results...
02/17/2023
Oncology
Conference Coverage
Neoadjuvant Chemotherapy Plus Tislelizumab Followed by Radiotherapy As Bladder-Preserving Treatment for Muscle-Invasive Urothelial Bladder Cancer
02/17/2023
According to study results presented at the 2023 ASCO GU Cancers Symposium, neoadjuvant chemotherapy plus tislelizumab followed by radiation for patients with muscle-invasive bladder cancer showed perfect efficacy and acceptable tolerability.
According to study results presented at the 2023 ASCO GU Cancers Symposium, neoadjuvant chemotherapy plus tislelizumab followed by radiation for patients with muscle-invasive bladder cancer showed perfect efficacy and acceptable tolerability.
According to study results...
02/17/2023
Oncology
Conference Coverage
Neoadjuvant Pembrolizumab Plus Chemotherapy to Induce Tumor Down-Staging for Muscle-Invasive Urothelial Carcinoma
02/17/2023
According to phase 1b/2 trial results presented at the 2023 ASCO Genitourinary Cancers Symposium, neoadjuvant chemo-immunotherapy resulted in down-staging prior to definitive surgery for patients with muscle-invasive urothelial carcinoma,...
According to phase 1b/2 trial results presented at the 2023 ASCO Genitourinary Cancers Symposium, neoadjuvant chemo-immunotherapy resulted in down-staging prior to definitive surgery for patients with muscle-invasive urothelial carcinoma,...
According to phase 1b/2 trial...
02/17/2023
Oncology
Scott Tagawa, MD, Weill Cornell Medicine
Videos
Anti-PSMA Salvage Radio-Immunotherapy for Castration-Resistant Prostate Cancer
02/16/2023
Scott Tagawa, MD, presents results from a phase 2 study evaluating anti-PSMA salvage radio-immunotherapy for patients with high-risk non-metastatic castration-resistant prostate cancer.
Scott Tagawa, MD, presents results from a phase 2 study evaluating anti-PSMA salvage radio-immunotherapy for patients with high-risk non-metastatic castration-resistant prostate cancer.
Scott Tagawa, MD, presents...
02/16/2023
Oncology
Conference Coverage
Talazoparib Plus Enzalutamide Improves PFS for Metastatic Castration-Resistant Prostate Cancer
02/16/2023
According to phase 3 interim data presented at the 2023 ASCO GU Symposium, talazoparib plus enzalutamide was superior to standard-of-care enzalutamide in imaging-based progression-free survival for patients with metastatic...
According to phase 3 interim data presented at the 2023 ASCO GU Symposium, talazoparib plus enzalutamide was superior to standard-of-care enzalutamide in imaging-based progression-free survival for patients with metastatic...
According to phase 3 interim...
02/16/2023
Oncology
Conference Coverage
Rucaparib Improved Survival Outcomes vs Docetaxel and Androgen Pathway Inhibitor Therapy Among Patients with Metastatic Castration-Resistant Prostate Cancer
02/16/2023
According to phase 3 interim data presented at the 2023 ASCO GU Symposium, rucaparib improved radiographic progression-free survival vs either docetaxel or abiraterone/enzalutamide for patients with metastatic castration-resistant prostate...
According to phase 3 interim data presented at the 2023 ASCO GU Symposium, rucaparib improved radiographic progression-free survival vs either docetaxel or abiraterone/enzalutamide for patients with metastatic castration-resistant prostate...
According to phase 3 interim...
02/16/2023
Oncology
Conference Coverage
Darolutamide Plus ADT and Docetaxel As a New Standard of Care for Hormone-Sensitive Prostate Cancer
02/16/2023
According to phase 3 trial data presented at the 2023 ASCO GU Symposium, darolutamide plus androgen-deprivation therapy and docetaxel improved the overall survival of patients with metastatic hormone-sensitive prostate cancer regardless of...
According to phase 3 trial data presented at the 2023 ASCO GU Symposium, darolutamide plus androgen-deprivation therapy and docetaxel improved the overall survival of patients with metastatic hormone-sensitive prostate cancer regardless of...
According to phase 3 trial data...
02/16/2023
Oncology
Conference Coverage
BXCL701/Talabostat As a Treatment Option for Refractory Metastatic Castration-Resistant Prostate Cancer of Small Cell Neuroendocrine Phenotype
02/16/2023
According to phase 2a trial results presented at the 2023 ASCO GU Symposium, the oral small molecule inhibitor of dipeptidyl peptidases, BXCL701, showed promise among patients with refractory metastatic castration-resistant prostate cancer of...
According to phase 2a trial results presented at the 2023 ASCO GU Symposium, the oral small molecule inhibitor of dipeptidyl peptidases, BXCL701, showed promise among patients with refractory metastatic castration-resistant prostate cancer of...
According to phase 2a trial...
02/16/2023
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use